Anbio BiotechnologyNNNN +2.88%24 Interest Coverage is No Debt (1) as of Dec. 2025, which is 100% below its 10-year median of 10,000.00. GuruFocus rates NNNN with a GF Score™ of 24/100. The stock has 2 warning signs investors should review. Among 466 Medical Devices & Instruments companies, Anbio Biotechnology ranks better than 99.57% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Anbio Biotechnology's
Operating Income
for the
six
months ended in Dec. 2025 was $2.40 Mil. Anbio Biotechnology's Interest Expense for the
six
months ended in Dec. 2025 was $0.00 Mil.
Anbio Biotechnology has no debt.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Anbio Biotechnology has no debt.
(1) Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
The historical rank and industry rank for Anbio Biotechnology's Interest Coverage or its related term are showing as below:
NNNN'
s Interest Coverage Range Over the Past 10 Years
Min: 1274.5 Med: No Debt Max: No Debt
Current: No Debt
NNNN's Interest Coverage is ranked better than 99.57% of 466
companies
in the Medical Devices & Instruments industry
Industry Median: 15.875
vs NNNN: No Debt
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Anbio Biotechnology Interest Coverage Related Terms
Anbio Biotechnology Interest Coverage Historical Data
* Premium members only.
The historical data trend for Anbio Biotechnology's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
NNNN vs ANGO, OSUR, UTMD: Interest Coverage Comparison
For the Medical Instruments & Supplies subindustry, Anbio Biotechnology's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anbio Biotechnology Interest Coverage vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Anbio Biotechnology's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Anbio Biotechnology's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Interest Coverage of No Debt <sup>(1)</sup> mean?
Anbio Biotechnology (NNNN) has a Interest Coverage of No Debt (1) as of Dec. 2025. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Anbio Biotechnology and its competitors. This is 100% below median its historical median of 10,000.00. Over the past decade, Anbio Biotechnology's Interest Coverage has ranged from 1,274.50 to 10,000.00. According to the industry distribution chart, Anbio Biotechnology ranks #2 out of 466 companies in the Medical Devices & Instruments industry, placing it in the top 0.40000000000001%.
Is Anbio Biotechnology's Interest Coverage too high?
Anbio Biotechnology's current Interest Coverage of No Debt (1) is 100% below median its 10-year median of 10,000.00. Over the past 10 years, this metric has ranged from a low of 1,274.50 to a high of 10,000.00. Based on the distribution chart, Anbio Biotechnology ranks #2 out of 466 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Anbio Biotechnology has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Anbio Biotechnology's Interest Coverage compare to ANGO and OSUR?
According to the Medical Devices & Instruments industry distribution chart, Anbio Biotechnology ranks #2 out of 466 companies for Interest Coverage. This places Anbio Biotechnology in the top 0% of its industry — outperforming the majority of peers. The industry median Interest Coverage is 15.88. Historically, Anbio Biotechnology's own Interest Coverage has ranged from 1,274.50 to 10,000.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Medical Devices & Instruments company?
The median Interest Coverage among Medical Devices & Instruments companies is 15.88, based on 466 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Anbio Biotechnology and its competitors. For the Medical Devices & Instruments industry, the median Interest Coverage is 15.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Anbio Biotechnology's current Interest Coverage is No Debt (1), which is 100% below median its own 10-year median of 10,000.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anbio Biotechnology stock overvalued right now?
Anbio Biotechnology (NNNN) has a current Interest Coverage of No Debt (1). The current Interest Coverage is No Debt (1), which is 100% below median its 10-year median of 10,000.00. Anbio Biotechnology's overall GF Score™ is 24/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Anbio Biotechnology (NNNN), the current Interest Coverage is No Debt (1) as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. The company's mission is to change the diagnostics market by personalizing and decentralizing the current diagnostic solutions for faster diagnosis to improve patient prognosis. The company proposes this by providing accessible and affordable diagnostic solutions globally at the forefront of science and offering laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions. The business planning is to focus on validating and commercializing the existing portfolio of in vitro diagnostic products, as well as generating additional data required to support regulatory submissions and compliance, including under frameworks such as the In Vitro Diagnostic Regulation (IVDR).
24GF Score
Get the complete analysis for NNNN
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NNNN has been successfully added to your 
